Source: International Congress 2015 – New data on established treatments for asthma and COPD
Disease area: Airway diseases

Abstract

Method: The study was conducted in women [aged 37] treated with steroids because of asthma in order to assess the activity of the brainstem. The study was conducted with the fMRI reader [3T GE] after the administration of beclomethasone(BC) at 250, 500 and 1000 µg or placebo. BC and placebo were administered every 14 days. To ensure the deposition of aerosol in the central-(CAD) or peripheral-(PAD) airways, applied inhalation chamber integrated with a spirometer [PNEUMOlogic^® abcMED] was used. Data analysis was performed using FSL, ImageJ integrated program of anatomical atlases. The data were averaged over intervals of 5 minutes. The first 0-5 min interval taken as reference. Changing the strength of the signal was calculated in standard deviation units for each subsequent five minute period. Results: placebo and BC showed a decrease in signal strength after inhalation with a central deposition of aerosol. After inhalation, with a predominance of peripheral deposition (PAD) placebo showed an increase in signal, whereas 250, 500 and 1000 µg of BC was found dose-dependent decrease in the signal.



Discussion: This is the first study to assess the impact of dose and space BC deposition on the function of selected brain structures. The study may be important for understanding the role of the knowledge of the brain and the need to harmonize the treatment of asthma with the brain.


Rating:

Share or cite this content

Citations should be made in the following way:
Zygmunt Podolec (Kraków, Poland), Zygmunt Podolec, Marcin Hartel, Daria Panek, Magdalena Podolec-Rubis, Tomasz Banasik. Effect of inhaled beclomethasone or placebo on brain stem activity in a patient chronically treated with steroids - Preliminary report. Eur Respir J 2015; 46: Suppl. 59, 1021

Member's Comments

No comment yet.

Related content which might interest you: Efficacy and safety of indacaterol acetate on ICS background therapy in asthma Source: International Congress 2014 – Asthma and COPD management Year: 2014 Once-daily tiotropium Respimat add-on to at least ICS in adult patients with symptomatic asthma: Pooled safety analysis Source: International Congress 2014 – Asthma and COPD management Year: 2014 Abediterol: Efficacy, safety and tolerability of the novel LABA in patients with persistent asthma Source: International Congress 2014 – Clinical trials of drugs for respiratory diseases Year: 2014 Efficacy and safety of inhaled corticosteroids in combination with a long-acting beta2-agonist in asthmatic children under age 5 Source: International Congress 2016 – Drugs, bugs, BMI, and other problems in paediatric asthma Year: 2016 Systemic exposure and lung bioavailability across two different dose strengths of CHF5993 a novel Triple pMDI Source: International Congress 2016 – Pulmonary drug delivery Year: 2016 Prescribed doses and effect on asthma treatment outcomes of extrafine (ciclesonide) vs standard particle inhaled corticosteroids (ICS) Source: International Congress 2015 – Novel targets and strategies for the treatment of cough, asthma, rhinosinusitis and COPD Year: 2015 Pharmacokinetics, safety and tolerability of CHF5993 a triple pMDI in renal impaired patients Source: International Congress 2016 – Novel avenues in the treatment of COPD I Year: 2016 Pearl's PT010 triple combination provides comparable budesonide exposure to symbicort and comparable glycopyrronium and formoterol exposure to PT003 Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Effect of QVA149 on lung function in the subgroup of patients with a history of exacerbations in the previous year and baseline ICS use from the SHINE study Source: International Congress 2014 – Asthma and COPD devices and treatments Year: 2014 Knemometry assessment of short-term lower leg growth in children with asthma treated with fluticasone propionate/formoterol combination therapy Source: International Congress 2015 – Paediatric asthma and allergy: asthma management Year: 2015 Efficacy and safety of VR475 (budesonide suspension delivered by the VR475 Inhalation System) as add-on treatment in patients with severe asthma (CLEARCUT Study) Source: International Congress 2019 – Asthma treatment: novel insights from clinical studies Year: 2019 Effect of aclidinium bromide/formoterol fumarate fixed-dose combination (FDC) on night-time and early morning symptoms in COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 Individual and differential treatment responses to once-daily long acting bronchodilators, glycopirronium and indacaterol, and combination of both drugs in the patients with moderate or severe COPD Source: International Congress 2014 – New clinical evidence for asthma and COPD treatments Year: 2014 24-h efficacy and pharmacokinetics of tiotropium Respimat® 5 μg in patients with asthma Source: International Congress 2015 – Immune mechanisms in the human lung Year: 2015 1-year efficacy and safety study of tiotropium respimat add-on to ICS in adolescent patients with symptomatic asthma Source: International Congress 2014 – Bronchodilators for asthma and COPD Year: 2014 Pharmacokinetics (PK) of indacaterol acetate and mometasone furoate delivered alone or in combination following once daily inhalation in healthy subjects Source: International Congress 2014 – Asthma and COPD management Year: 2014 LATE-BREAKING ABSTRACT: A dose-ranging study of dupilumab in patients (pts) with uncontrolled asthma despite use of inhaled corticosteroids plus a long-acting beta-agonist (ICS/LABA): Final data Source: International Congress 2015 – Hot topics on airway diseases: new horizons in treatment Year: 2015 Comparative efficacy and costs of the treatment of moderate to severe persistent asthma with a new dry-powder inhaled beclomethasone dipropionate and formoterol combination Source: Annual Congress 2013 –Health economics of airway diseases Year: 2013 Comparative assessment of umeclidinium/vilanterol (UMEC/VI) combination therapy among symptomatic COPD patients Source: International Congress 2014 – Asthma and COPD management Year: 2014 Phase III trial of tiotropium as add-on therapy to low-dose inhaled corticosteroids for patients with symptomatic mild persistent asthma: Design and planned analyses Source: Annual Congress 2013 –Asthma drugs: new findings Year: 2013